Hurtado Villarejo, BegoñaTrakala, MariannaXimenez-Embun, PilarEl Bakkali, AichaPartida, DavidSanz-Castillo, BelénAlvarez Fernandez, MonicaMaroto, MaríaSánchez-Martínez, RuthMartinez Garcia, Maria DoloresMuoz Peralta, JavierGarcía de Frutos, PabloMalumbres Martinez, Marcos2018-10-242018-10-242018-09-25J Clin Invest.2018 ; pii: 1218761558-8238http://hdl.handle.net/20.500.12105/6505MASTL, a Ser/Thr kinase that inhibits PP2A-B55 complexes during mitosis, is mutated in autosomal dominant thrombocytopenia. However, the connections between the cell cycle machinery and this human disease remain unexplored. We report here that, whereas Mastl ablation in megakaryocytes prevented proper maturation of these cells, mice carrying the thrombocytopenia-associated mutation developed thrombocytopenia as a consequence of aberrant activation and survival of platelets. Activation of mutant platelets was characterized by hyper-stabilized pseudopods mimicking the effect of PP2A inhibition and actin polymerization defects. These aberrations were accompanied by abnormal hyper-phosphorylation of multiple components of the actin cytoskeleton and were rescued both in vitro and in vivo by inhibiting upstream kinases such as PKA, PKC, or AMPK. These data reveal an unexpected role of Mastl in actin cytoskeleton dynamics in postmitotic cells, and suggest that the thrombocytopenia-associated mutation in MASTL is a pathogenic dominant mutation that mimics decreased PP2A activity resulting in altered phosphorylation of cytoskeletal regulatory pathways.engVoRCell BiologyCell cycleHematologyPhosphoprotein phosphatasesThrombosisAtribución 4.0 Internacional3025267810.1172/JCI1218761558-8238The Journal of clinical investigationopen access